Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 0.2% – Still a Buy?

Posted by Francis Steltz on Oct 29th, 2026

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report)’s share price was up 0.2% on Tuesday. The stock traded as high as $4.29 and last traded at $4.17. 245,240 shares were traded during trading, The stock had previously closed at $4.16.

Analysts Set New Price Targets

A number of equities analysts have issued reports on AVIR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Morgan Stanley increased their price target on Atea Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $7.00.

Read Our Latest Research Report on AVIR

Atea Pharmaceuticals Stock Up 0.9%

The firm has a market cap of $345.68 million, a price-to-earnings ratio of -2.07 and a beta of 0.39. The company has a 50-day moving average price of $5.09 and a 200 day moving average price of $4.90.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.15. Equities analysts forecast that Atea Pharmaceuticals, Inc. will post -1.99 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Atea Pharmaceuticals during the second quarter worth $40,548,000. Arrowstreet Capital Limited Partnership bought a new position in Atea Pharmaceuticals during the first quarter valued at about $1,133,000. Hsbc Holdings PLC bought a new position in Atea Pharmaceuticals during the second quarter valued at about $1,023,000. Bank of New York Mellon Corp acquired a new stake in shares of Atea Pharmaceuticals in the second quarter worth about $881,000. Finally, Irenic Capital Management LP acquired a new stake in shares of Atea Pharmaceuticals in the first quarter worth about $1,623,000. 86.67% of the stock is owned by hedge funds and other institutional investors.

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral therapies for serious infectious diseases. The company’s research platform is based on nucleotide and nucleoside prodrug technologies designed to target viral replication.

Atea’s lead product candidate is bemnifosbuvir, formerly known as AT-527, an orally administered antiviral that has been evaluated for the treatment of COVID-19. The company has also investigated bemnifosbuvir and related antiviral approaches for other viral infections, including hepatitis C.